Insulet Corporation Market Research Report

Company Overview

• Name: Insulet Corporation

• Mission: To improve the lives of people with diabetes and enable customers to enjoy simplicity, freedom, and healthier lives through innovative technology.

• Founded: 2000

• Founder: A father determined to help his son manage diabetes.

• Headquarters: Acton, Massachusetts, USA

• Number of Employees: No information is available.

• Revenue: $1.7 billion in total annual revenue.

• Known For: Insulet is known for the Omnipod, a tubeless insulin management system that offers continuous insulin delivery.

Key People

• Rahul Sarvadevabhatla: Director of Life Cycle Engineering.

• Maria Urbina: Associate Product Manager and Podder.

Products

Omnipod

• Description: The Omnipod system is a tubeless, wearable, and waterproof insulin delivery system designed for continuous insulin delivery.

• Key Features:

• Tubeless: Allows freedom in activities and wardrobe choices.

• Wearable and Waterproof: Rated IP28 for immersion up to 25 feet for up to 60 minutes.

• No Multiple Daily Injections: Automates insulin delivery through a pod, with up to three days of continuous service.

Omnipod 5 System

• Description: Omnipod 5 is an FDA-approved automated insulin delivery system for both type 1 and type 2 diabetes, offering remote control via compatible smartphones.

• Key Features:

• Automated Insulin Delivery: SmartAdjust™ technology integrates with continuous glucose monitors (CGMs) for automated insulin management.

• Mobile App Control: Allows users to manage their diabetes remotely through a mobile device.

• Suitable for Ages: Type 1 diabetes from age 2+, Type 2 diabetes for adults 18+.

Recent Developments

• New Products: The Omnipod 5 Automated Insulin Delivery System, now cleared for type 2 diabetes management.

• New Features: The Omnipod 5 app for iPhone integration, allowing easier control via smartphones.

• New Partnerships: No specific partnership information available.

• Infrastructure Development: Opened a new manufacturing facility in Johor Bahru, Malaysia, doubling the size of their existing facility in Acton, Massachusetts, to meet growing demand and align with sustainability goals.

Markets

• Countries Offering Omnipod: Available in 25 countries, including those in North America, Europe, the Middle East, and Asia Pacific.

Innovations and Impact

• Sustainability Efforts: Insulet’s new manufacturing facility in Malaysia was designed with sustainable elements to achieve Green Building Index (GBI) certification and Leadership in Energy and Environmental Design (LEED) Silver certification.

• Social Impact: Insulet is active in creating positive social impacts and an inclusive workplace culture, advocating for their customers, known affectionately as Podders.

Conclusion

Insulet Corporation stands as a leader in insulin delivery technology with its flagship product, Omnipod. The recent introduction of the Omnipod 5 system with mobile app control and FDA clearance for broader diabetes management exemplifies the company’s commitment to innovate and improve lives. With a robust sustainability strategy and plans for continued global expansion, Insulet remains poised for significant growth and influence in the diabetes care landscape.